Phase 1
Completed N=12
The Effects of Castration on the Pharmacokinetics of Zolpidem After Single Dose Administration In Men With Prostate Cancer Undergoing Androgen Deprivation Therapy Compared to Normal Healthy Females
Source: ClinicalTrials.gov NCT03436745 ↗Enrolled (actual)
12
Serious AEs
0.0%
Results posted
Feb 2025
Primary outcomePrimary: Change in Area Under the Plasma Concentration 0-8Hour (Hr)(AUC0-8hr) Values in Males Between Pre-Androgen Deprivation Therapy (ADT) and Post-ADT — 484.65; 473.05 Hr*ng/mL
Summary
Background:
Insomnia is associated with difficulty sleeping. The drug zolpidem is widely prescribed for insomnia. Women have reported worse effects from the drug than men. Women have higher amounts of zolpidem in their body that may persist after waking. Drug exposure may also depend on male hormones that change during prostate cancer therapy. Researchers want to see if these findings can provide a more-accurate dose to healthy women and men with prostate cancer.
Objective:
To study amounts of zolpidem in men who have been diagnosed with prostate cancer before they are castrated and after, and to compare these results to healthy women s.
Eligibility:
Men ages 18 and older who have been diagnosed with prostate cancer who are planning to receive androgen deprivation therapy (ADT)
Healthy women age 18 and older
Design:
Participants will be screened with:
Blood tests
Physical exam
Electrocardiogram (EKG) heart test
Male participants will confirm their prostate cancer. This can be done with a tumor sample tissue from a previous surgery or a report from a doctor.
Female participants may have a pregnancy test.
Participants will be admitted to the clinic in the evening and stay overnight. They will:
Take a 5 mg zolpidem tablet on an empty stomach around 11 p.m.
Have blood drawn multiple times
Have physical exams and EKGs
Answer questions about their symptoms and medicines they are taking
Male participants will have ADT as part of their standard cancer treatment. After that, the testosterone in their blood will be measured. They will repeat the overnight clinic stay.
Participants will get a follow-up phone call after each stay.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change in Area Under the Plasma Concentration 0-8Hour (Hr)(AUC0-8hr) Values in Males Between Pre-Androgen Deprivation Therapy (ADT) and Post-ADT |
484.65; 473.05 | — |
| SECONDARY Comparison of Area Under the Plasma Concentration 0-8Hour (Hr)(AUC0-8hr) Values Between Post-Androgen Deprivation Therapy (ADT) Males and Healthy Female Participants |
242; 473.05 | — |
Eligibility Criteria
- INCLUSION CRITERIA - FOR MALE COHORT:
- Patients must have histologically or cytologically confirmed prostate cancer. Note: If histologic documentation is unavailable, a clinical course consistent with prostate cancer is acceptable.
- Patients must be eligible for and must be planning to undergo androgen deprivation therapy
- Testosterone levels greater than or equal to 100 ng/dL
- Patients must have progressive prostate cancer as indicated by either prostate-specific antigen (PSA) progression (PSA progression is defined as two consecutively rising PSAs above the nadir post- definitive therapy and an absolute value greater than 1.0 ng/mL separated by at least 2 weeks) or radiographic progression based on Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 or Prostate Cancer Working Group 3 (PCWG3).
- Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1
- Patients must have normal organ and marrow function as defined below:
- Hemoglobin greater than or equal to 9 g/dL
- leukocytes greater than or equal to 3,000/mcL
- absolute neutrophil count greater than or equal to 1,500/mcL
- platelets greater than or equal to 150,000/mcL
- total bilirubin within normal institutional limits
- Aspartate aminotransferase (AST)/serum glutamic-oxaloacetic transaminase (SGOT)/alanine aminotransferase (ALT) serum glutamic-pyruvic transaminase (SGPT) less than or equal to institutional upper limit of normal
- creatinine within normal institutional limits OR creatinine clearance greater than or equal to 60 mL/min/1.73 m^2 for patients with creatinine levels above institutional normal (calculated via Cockcroft-Gault equation)
- Patients must not have other concurrent malignancies (within the past 2 years with the exception of non-melanoma skin cancer and Rai Stage 0 chronic lymphocytic leukemia), in situ carcinoma of any site, or life-threatening illnesses, including untreated infection (must be at least 1 week off intravenous antibiotic therapy before beginning zolpidem).
- Ability of subject to understand and the willingness to sign a written informed consent document.
- Ability to swallow study medication.
- Willingness to travel to National Institutes of Health (NIH) for follow-up visits.
- Men age greater than or equal to 18 years of age. Children are excluded because prostate cancer is not common in pediatric populations.
INCLUSION CRITERIA - FOR NORMAL HEALTHY FEMALE COHORT:
- Females age greater than or equal to 18 years of age
- Good health conditions or without significant diseases, according to best medical judgement.
- If breastfeeding, must be willing to discard breastmilk for 24 hours following zolpidem.
- Ability if subject to understand and the willingness to sign a written informed consent Ability to swallow study medication.
EXCLUSION CRITERIA - FOR MALE COHORT:
- Patients who are receiving any other investigational agents (in the past 28 days) or herbal medications (within 1 day).
- Patients who have received systemic chemotherapy for prostate cancer will not be eligible.
- Known hypersensitivity to Zolpidem or chemically related compounds; history of serious adverse reactions or hypersensitivity to any drug.
- Clinically significant cardiac disease, e.g. New York Heart Association (NYHA) classes III-IV; uncontrolled angina, uncontrolled arrhythmia or uncontrolled hypertension, myocardial infarction in the previous 6 months as confirmed by an electrocardiogram (ECG).
- Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
- Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with zolpidem. Appropriate studies will be undertaken in patients receiving combination antiretroviral the
Data sourced from ClinicalTrials.gov (NCT03436745). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.